arrow
S

Sanna Toppila-Salmi

University of Eastern Finland
H指数:46
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Achieving Remission in Chronic Rhinosinusitis With Nasal Polyps Depends on Practical Utilization of Current Criteria and Does not Reflect Therapy Response: Results From a Multi-National Cohort

在鼻息肉慢性鼻窦炎中实现<i>缓解</i>依赖于对当前标准的实际应用,并不反映疗法<i>应答</i>:多国队列研究的结果

2026-10-050
OAAI
As-Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK-air Study

花粉季节过敏性鼻炎治疗中按需用药与常规用药的比较:一项MASK-air研究

2026-09-100
OAAI
ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases

ARIA-EAACI 2025:气道疾病中以患者为中心、数字化赋能和人工智能辅助的变革管理

2026-09-030
OAAI
Surgical Management of Non-Allergic Rhinitis—An EAACI Task Force Position Paper

非过敏性鼻炎的外科治疗——EAACI工作组立场文件

2026-07-010
OAAI
Distinction between allergic rhinitis alone and allergic rhinitis plus asthma in MASK-air ® real-world studies; a ARIA-WAO task force review

MASK-air ®真实世界研究中单纯过敏性鼻炎与过敏性鼻炎合并哮喘的区分;一项ARIA-WAO工作组综述

2026-07-010
OAAI
Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK-air Study

过敏性鼻炎治疗方法在效用和生活质量方面的比较:一项MASK-air研究

2026-05-060
OAAI
Discovering Age- and Sex-Specific Genetic Risk Factors in Sensorineural Hearing Loss: Genome-Wide Evidence from Large-Scale Biobanks

在感音神经性听力损失中发现年龄和性别特异的遗传风险因素:来自大规模生物样本库的全基因组证据

2026-05-010
OA
The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Utricaria, and Chronic Rhinosinusitis With Nasal Polyps

首个用于过敏领域的生物类似药:CT-P39(Omlyclo-Omalizumab-Igec)适用于哮喘、慢性自发性荨麻疹和伴有鼻息肉的慢性鼻窦炎

2026-04-250
PRE
Meta-Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force

系统性糖皮质激素在炎症性上呼吸道疾病和哮喘中的危害:EAACI工作组荟萃分析

2026-04-010
PRE
Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part II—Guidelines on Oral and Ocular Treatments

变应性鼻炎及其对哮喘的影响(ARIA)-EAACI指南—2024–2025年修订版:第II部分—口服和眼部治疗指南

2026-03-240
OAAI
Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

慢性鼻鼻窦炎和哮喘合并症: 共同的危险因素和治疗意义-EAACI工作组报告

2026-02-050
PREAI
Updated Treatment of Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report

非甾体类抗炎药加重呼吸系统疾病的更新治疗: 脱敏或生物制剂后如何决定阿司匹林治疗?什么时候?怎么?EAACI特别工作组报告

2026-02-050
PRE
The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways—An EAACI Position Paper

上气道炎症性疾病中嗅觉测试的未满足需求——EAACI立场文件

2026-02-020
PRE
Development and psychometric validation of the Chronic Rhinosinusitis Control Test

慢性鼻窦炎控制测试的开发与心理测量学验证

2026-01-012
PRE
Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

变应性鼻炎及其对哮喘的影响(ARIA)-EAACI指南—2024–2025年修订版:第一部分—关于鼻内治疗的指南

2025-12-010
OAAI
Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms

过敏性鼻炎及其对哮喘的影响(ARIA)-EAACI 2024–2025指南的开发方法:从证据到决策框架到数字化共享决策算法

2025-11-210
OAAI
Assessment of the Effectiveness of Allergic Rhinitis Medications Using a Target Trial Emulation Approach Based on Mobile Health Data

基于移动健康数据,采用目标试验模拟方法评估过敏性鼻炎药物的有效性

2025-11-010
OAAI
Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report

过敏性鼻炎治疗对患者满意度的影响比较:一项MASK-air和EAACI方法学委员会报告

2025-09-260
OAAI